Immuno-Oncology & Immunotherapy

Immuno-oncology (I/O) has become a significant opportunity for oncology drug discovery and development. The ability to harness each person's unique immune system in a meaningful to dampen the deadly effects of tumor cells has created the explosion of precision medicine. Integrate your flow cytometry, efficacy models, imaging, biomarker, and companion diagnostics to quickly advance to the next milestone--because patients can't wait. 

  • Access over 30 different syngeneic tumor models, from both solid and disseminated origins as well as access to commercially generated humanized mouse models or client-generated models.

  • Draw on over 1000 immuno-oncology clinical study experience in the last 10 years. 

  • Partner with an oncology CRO provider who has served nearly 20,000 immuno-oncology patients in clinical trials in the last 5 years. 

Cheerful Young bald woman | Immuno-oncology precision treatment | CRO

临床前免疫治疗

It is essential to meaningfully assess the immune effector cells involved in the development of a particular tumor model and those involved in mediating the anti-tumor response of individual therapeutics. For many of our models, we have growth curves available, and we continue to build our database with treatment response to agents of interest like anti-CTLA-4, anti-PDL-1, and anti-PD-1 antibodies.

In addition to testing immune-modulating agents themselves or testing other agents in combination with immune-modulators, it is important to consider the impact of radiation therapy, which is being integrated into and increasingly investigated in combination with these immuno-oncology protocols. Data showing abscopal effects of radiotherapy and immune modulators, along with direct combination anti-tumor effects, has provided proof-of-concept and is attracting further investigation of this highly utilized, clinically relevant modality in the preclinical setting.

Clinical Immuno-oncology

要使精准医疗取得成效,必须采用创新方法进行快速试验,并向合适的个人提供合适的疗法。科文斯在肿瘤免疫研究方面拥有成熟经验,其中包括过去五年在58个国家的超过2,860个试验地点完成了100项试验计划,涉及的患者逾19,750人。

Our commitment to immuno-oncology is also evident through our support of more than 70% of all FDA-approved companion diagnostic products. As part of a recent pivotal Phase III registration trial, our central laboratory was the sole provider of testing for PD-L1 expression, which led to a new FDA-approved diagnostic test for OPDIVO® (nivolumab).此外,我们同类最佳的伴随诊断能力支持TagrissoTM(osimertinib)及其EGFR突变试验以及免疫疗法Keytruda®(pembrolizumab)及其PD-L1伴随诊断通过了审批。 

Immuno-oncology Educational Resources

Whether you identify as a large pharma company with many assets in the pipeline or a biotech with an emerging portfolio, we have resources to help you at each point in your journey. Browse our clinical educational immuno-oncology resources by what best identifies your company's pipeline: